CliffBio
biologic

Aimovig

erenumab-aooe

Loss of exclusivityMay 2030projected — 12-year biologic exclusivity estimate
CompanyAmgen →View the full company profile on CliffBio

Drug detail

Brand nameAimovig
Active ingredienterenumab-aooe
Strength70MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2018
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Aimovig patent cliff — loss of exclusivity May 2030 | CliffBio